Albumin-Bound Paclitaxel
Showing 1 - 25 of 4,668
PDAC - Pancreatic Ductal Adenocarcinoma Trial (Combination of sitagliptin+ gemcitabine + nab-paclitaxel)
Not yet recruiting
- PDAC - Pancreatic Ductal Adenocarcinoma
- Combination of sitagliptin+ gemcitabine + nab-paclitaxel
- (no location specified)
Jul 9, 2023
Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous NSCLC, Metastatic Non-squamous Non Small Cell Lung
Not yet recruiting
- Advanced Non-squamous Non-small-cell Lung Cancer
- +2 more
- pembrolizumab
- +2 more
-
Beijing, Beijing, ChinaPeking University First Hospital Ethics Committee
Sep 10, 2023
Breast Cancer Trial in Chengdu (Pyrotinib combined with albumin-bound paclitaxel and trastuzumab)
Recruiting
- Breast Cancer
- Pyrotinib combined with albumin-bound paclitaxel and trastuzumab
-
Chengdu, Chengdu, Sichuan, China, ChinaWest China Hospital, Sichuan University
Oct 7, 2022
Locally Advanced Pancreatic Cancer Trial in Shanghai (Tumor treating fields combined with Gemcitabine HCl and albumin binding
Not yet recruiting
- Locally Advanced Pancreatic Cancer
- Tumor treating fields combined with Gemcitabine hydrochloride and albumin binding paclitaxel
- Gemcitabine hydrochloride and albumin binding paclitaxel
-
Shanghai, Shanghai, ChinaHuashan Hospital Affiliated to Fudan University
Dec 8, 2022
Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Recurrent Ovarian Carcinoma Trial in Beijing (Albumin-bound paclitaxel and
Recruiting
- Ovarian Carcinoma
- +6 more
- Albumin-bound paclitaxel and bevacizumab
-
Beijing, Beijing, ChinaLei Li
Mar 26, 2022
Gastric Cancer, GastroEsophageal Cancer Trial in Wuhan (Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor), Albumin-bound
Active, not recruiting
- Gastric Cancer
- GastroEsophageal Cancer
- Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor)
- Albumin-bound Paclitaxel
-
Wuhan, Hubei, ChinaTongji hospital of Tongji Medical College, Huazhong University o
Jan 21, 2023
Recurrent Cervical Cancer Trial in Guangzhou (anti-PD-1+Albumin-Bound Paclitaxel)
Active, not recruiting
- Recurrent Cervical Cancer
- anti-PD-1+Albumin-Bound Paclitaxel
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
May 26, 2022
Early Breast Cancer Trial in Zhengzhou (monosialic gangliosides, Placebo)
Withdrawn
- Early Breast Cancer
- monosialic gangliosides
- Placebo
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital
Nov 19, 2022
Breast Cancer Trial in Beijing (doxorubicin, epirubicin, pirarubicin)
Not yet recruiting
- Breast Cancer
- doxorubicin
- +6 more
-
Beijing, Beijing, ChinaCancer Hospital, ChineseAMS
Mar 17, 2022
Angiosarcoma Metastatic Trial in Guangzhou (Abraxane combined with liposomal doxorubicin)
Recruiting
- Angiosarcoma Metastatic
- Abraxane combined with liposomal doxorubicin
-
Guangzhou, Guangdong, ChinaXing Zhang
Sep 4, 2022
Pancreatic Cancer Trial in Tianjin (surufatinib + gemcitabine + nab-paclitaxel)
Recruiting
- Pancreatic Cancer
- surufatinib + gemcitabine + nab-paclitaxel
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Jun 15, 2023
Ovarian Cancer Trial (albumin-bound paclitaxel, paclitaxel)
Not yet recruiting
- Ovarian Cancer
- albumin-bound paclitaxel
- paclitaxel
- (no location specified)
Mar 31, 2022
Advanced Gastric Adenocarcinoma Trial in Ho-nan (Camrelizumab, Albumin-bound paclitaxel, S-1)
Recruiting
- Advanced Gastric Adenocarcinoma
- Camrelizumab, Albumin-bound paclitaxel, S-1
-
Ho-nan, Henan, ChinaHenan Tumor Hospital
Apr 14, 2022
Breast Cancer Trial in Beijing (Inetetamab, Toripalimab, Albumin-Bound Paclitaxel)
Not yet recruiting
- Breast Cancer
- Inetetamab
- +2 more
-
Beijing, ChinaCancer Hospital Chinese Academy Of Medical Sciences
Mar 14, 2022
HNSCC, Oral Cancer, PD-1 Trial in Guangzhou (Perbolizumab+Carboplatin+albumin-bound paclitaxel:4 courses,
Recruiting
- HNSCC
- +2 more
- Perbolizumab+Carboplatin+albumin-bound paclitaxel:4 courses
- Perbolizumab+Carboplatin+albumin-bound paclitaxel:2 courses
-
Guangzhou, Guangdong, ChinaSun yat-sen memorial hospital
Aug 6, 2023
Triple-negative Breast Cancer Trial in Bengbu (Albumin-Bound Paclitaxel, Apatinib Mesylate, Bevacizumab)
Recruiting
- Triple-negative Breast Cancer
- Albumin-Bound Paclitaxel
- +2 more
-
Bengbu, Anhui, ChinaDepartment of Medical Oncology, First Affiliated Hospital of Ben
Mar 15, 2022
Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma Trial in United States (Laboratory
Active, not recruiting
- Locally Advanced Breast Carcinoma
- +7 more
- Laboratory Biomarker Analysis
- +2 more
-
Duarte, California
- +3 more
Jan 31, 2023
Advanced Urothelial Carcinoma Trial in Beijing (anti-PD-L1 antibody, albumin bound paclitaxel)
Active, not recruiting
- Advanced Urothelial Carcinoma
- anti-PD-L1 antibody
- albumin bound paclitaxel
-
Beijing, Beijing, ChinaBeijing Tumor Hospital
Jan 20, 2022
Soft Tissue Sarcoma Trial in Zhengzhou (Albumin-Bound Paclitaxel, Camrelizumab)
Recruiting
- Soft Tissue Sarcoma
- Albumin-Bound Paclitaxel
- Camrelizumab
-
Zhengzhou, Henan, ChinaDepartment of Bone and Soft Tissue, Henan Cancer Hospital
Jan 13, 2022
Solid Tumor, Adult Trial (EOC202, albumin-bound paclitaxel)
Not yet recruiting
- Solid Tumor, Adult
- EOC202
- albumin-bound paclitaxel
- (no location specified)
Apr 7, 2022
Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (Anti-PD-1 antibody camrelizumab,
Recruiting
- Recurrent Cervical Carcinoma
- +5 more
- Anti-PD-1 antibody camrelizumab
- Albumin-bound paclitaxel
-
Beijing, Beijing, ChinaLei Li
Mar 12, 2022
Cervical Cancer Trial in Beijing (HLX10+Albumin-Bound Paclitaxel)
Active, not recruiting
- Cervical Cancer
- HLX10+Albumin-Bound Paclitaxel
-
Beijing, ChinaCancer Hospital, Chinese Academy of Medical Sciences
May 4, 2022
Second Line Treatment of Gastric Cancer Trial (Camrelizumab, Albumin-Bound Paclitaxel, Irinotecan)
Not yet recruiting
- Second Line Treatment of Gastric Cancer
- Camrelizumab
- +2 more
- (no location specified)
Dec 20, 2022
Gastric Cancer Trial in Wuhan (Albumin-bound Paclitaxel plus S-1, Oxaliplatin plus S-1)
Recruiting
- Gastric Cancer
- Albumin-bound Paclitaxel plus S-1
- Oxaliplatin plus S-1
-
Wuhan, Hubei, ChinaTongji hospital of Tongji Medical College, Huazhong University o
Jan 3, 2022